Catalent, Inc. (NYSE:CTLT) Receives Consensus Rating of “Hold” from Brokerages

Catalent, Inc. (NYSE:CTLT) has received a consensus rating of “Hold” from the seven ratings firms that are currently covering the company, Marketbeat reports. Seven research analysts have rated the stock with a hold rating. The average twelve-month target price among brokers that have covered the stock in the last year is $63.40.

A number of equities research analysts recently commented on CTLT shares. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. StockNews.com lowered shares of Catalent from a “hold” rating to a “sell” rating in a report on Friday, November 22nd. Finally, Robert W. Baird restated a “neutral” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th.

Insider Activity

In other news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,114 shares of company stock valued at $305,931. Corporate insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

Several hedge funds have recently bought and sold shares of the business. Brooklyn Investment Group bought a new position in shares of Catalent during the third quarter valued at approximately $31,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Catalent in the 2nd quarter worth approximately $42,000. Sentry Investment Management LLC bought a new position in Catalent during the 3rd quarter valued at approximately $53,000. Longfellow Investment Management Co. LLC raised its stake in Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after buying an additional 305 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after acquiring an additional 212 shares in the last quarter.

Catalent Stock Up 0.2 %

CTLT opened at $61.11 on Monday. Catalent has a 12 month low of $36.74 and a 12 month high of $61.50. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The business’s 50-day moving average price is $59.90 and its 200-day moving average price is $58.51. The company has a market cap of $11.09 billion, a P/E ratio of -27.04, a P/E/G ratio of 2.43 and a beta of 1.16.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same period last year, the firm earned ($0.10) earnings per share. Catalent’s revenue for the quarter was up 4.2% on a year-over-year basis. On average, equities analysts expect that Catalent will post 0.84 EPS for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.